Oppenheimer Maintains Their Buy Rating on KemPharm (KMPH)

In a report released today, Esther Rajavelu from Oppenheimer maintained a Buy rating on KemPharm (NASDAQ: KMPH), with a price target of $11. The company’s shares opened today at $2.60, close to its 52-week low of $2.46.

Rajavelu commented:

“We attended a Key Opinion Leaders (KOL) event hosted by KMPH to discuss Disorder (ADHD) treatment trends in adults and children. Recall KMPH plans to file KP415 for pediatric ADHD in 1Q19, and KP484 for adult ADHD later in 2019, both prodrugs of dexmethylphenidate (dMPH). The key takeaway, in our view, is that KP415 (if approved) could be widely prescribed to current methylphenidate patients (a meaningful switch population), assuming coverage and access parity. We maintain our Buy rating on KMPH with an $11 price target and look forward to the next several months, which may include important catalysts for the stock.”

According to, Rajavelu is ranked #4486 out of 4897 analysts.

Currently, the analyst consensus on KemPharm is a Moderate Buy with an average price target of $11.

See today’s analyst top recommended stocks >>

Based on KemPharm’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.99 million. In comparison, last year the company had a GAAP net loss of $9.98 million.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KMPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

From Our Partners